The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of one or more target antigens. In addition, the present invention relates to nucleic acid molecules encoding such modfied ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the modified ABMs of the invention, and to methods of using these modified ABMs in treatment of disease. In addition, the present invention relates to modified ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.本發明係關於改質抗原結合分子(ABM)。在特定實施例中，本發明係關於包括嵌合、靈長類化或人類化抗體或片段之重組單株抗體或片段，其具有改變藉由靶標抗原所調介細胞傳訊活性之能力及/或改變一或多種靶標抗原交聯之調介之能力。此外，本發明係關於編碼此等改質ABM之核酸分子以及含有此等核酸分子之載體及宿主細胞。本發明進一步係關於用於產生本發明改質ABM之方法及在疾病治療中使用此等改質ABM之方法。此外，本發明係關於具有改質之糖基化且具有改良之治療性質的改質ABM，包括Fc受體結合增強且效應功能增強之抗體。
